Faes Farma Completes Acquisition of Sifi for €270 Million

Faes Farma, a Spanish pharmaceutical company, has signed an agreement to acquire 100% of Sifi, an Italian ophthalmology-focused pharmaceutical firm, for an enterprise value of €270 million. The acquisition is expected to close in the third quarter of 2025, marking a significant step for Faes Farma's strategy to enhance its presence in the ophthalmology sector. 21 Invest, the private equity firm founded by Alessandro Benetton, will exit its investment in Sifi through this transaction, having transformed the company into a solid player in the global ophthalmology landscape. The deal allows Faes Farma to gain access to Sifi's established pharmaceutical activities, a third-party manufacturing unit, and Akantior, a newly approved therapeutic product for ultra-rare diseases in Europe. With this acquisition, Faes Farma aims to unlock synergies, drive operational efficiencies, and expand its reach into new European markets, while consolidating its positions in existing ones like Spain and Mexico. The integration of Sifi, alongside Faes Farma's recent acquisition of Edol, positions ophthalmology as a strategic growth area for the company.